Peter Bak public
[search 0]
More
Download the App!
show episodes
 
Artwork

1
Back Bay Life Science Report

Jonathan P. Gertler and Peter Bak

Unsubscribe
Unsubscribe
Monthly
 
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, ...
  continue reading
 
Loading …
show series
 
Irriterende Stortingsdebatter som spinner ut av kontroll, mindre Cola Zero-drikking på Stortinget, og var Ernas rabarbrasaft-video iscenesatt? Støre reagerer på «Basic bitch»-kommentar, men vet han hva det begrepet betyr? En podkast av Henrik Asheim, Tina Bru og Peter Frølich Hosted on Acast. See acast.com/privacy for more information.…
  continue reading
 
I ukens episode har vi en gjest vi aldri trodde ville stille i podkasten. Vi har et tema som er et av de aller viktigste i vår tid, men det er ikke snakk om liv eller død. Fredrik Solvang er på plass, og vi tar debatten om Debatten! En podkast av Henrik Asheim, Tina Bru og Peter Frølich Hosted on Acast. See acast.com/privacy for more information.…
  continue reading
 
In this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US exchange. Topics in this podcast include: An overview of the decision-making process through execution for US-based and ex-US healthcare companies thinking about listing in the US Core considerations …
  continue reading
 
Guests: Pete Bak and Christian Thienel Length: 27 minutes In this episode of The Life Science Report, Dr. Pete Bak and Back Bay Director, Christian Thienel catch up on the area attracting the most industry interest over the past couple of years: the anti-obesity space. From big players looking to capitalize on the renewed interest in the obesity sp…
  continue reading
 
Tina tar ikke gjenvalg til Stortinget og opplever litt for mange klamme omfavnelser. Sp jobber på spreng for å ikke få vedtatt regjeringens politikk. Og må folk slutte å henge med huet i verdens mest fantastiske helsevesen som skal bli enda mer fantastisk nå? En podkast av Henrik Asheim, Tina Bru og Peter Frølich Hosted on Acast. See acast.com/priv…
  continue reading
 
Welcome to another episode with the DNB//Back Bay Partnership for Healthcare. In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined by James Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director of US Equity Capital Markets at DNB, and Vasilios Kofitsas, Managing Director of Investment B…
  continue reading
 
Guests: Pete Bak and Christian Thienel Length: 37 minutes With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding the tailwind and developing vaccine therapies that span across viral illness, maternal infections and bacterial infections. In this episode resident imm…
  continue reading
 
A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and Psychedelics Guests: Pete Bak and Christian Thienel Length: 25 minutes Here at Back Bay we’ve seen a number of notable trends in the radiopharmaceutical and psychedelic spaces playing out over the past couple of years. Increasingly, investors have been asking our…
  continue reading
 
As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRISPR and Vertex approval of Exa-cel, Biogen and Sage’s August approval of an oral treatment for women with postpartum depression and Genmab and Roche’s May approval in oncology. In this…
  continue reading
 
In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in treatment, some recent commercial launches and certainly some interest from pharma consolidators, as M&A activity picks up in this area. In this next installment of The Life Science R…
  continue reading
 
With the DNB//Back Bay Partnership for Healthcare In the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets there’s been roughly $2.5B raised from an IPO standpoint YTD. In Europe, the markets have been more challenging, with IPOs for five companies going public…
  continue reading
 
Ny uke, ny habilitetssak! Men det skjer mye annet også. Energiministeren har vært i Brussel og Støre har fått huden full av twittertroll fra talerstolen. Vi oppsummerer en uke med proteksjonisme, nasjonalisme og populisme. En podkast av Henrik Asheim, Tina Bru og Peter Frølich Hosted on Acast. See acast.com/privacy for more information.…
  continue reading
 
Tilliten til politikerne har fått seg et skudd for baugen de siste månedene. Kan vi egentlig stole på at Henrik, Tina og PC vil levere ukentlig podkast fremover? Foreløpig er i hvert fall Stortingsrestauranten tilbake! En podkast av Henrik Asheim, Tina Bru og Peter Frølich Hosted on Acast. See acast.com/privacy for more information.…
  continue reading
 
A conversation on the rising trends in the cardiology space Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology. During this epis…
  continue reading
 
In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including: Background information on the class of ther…
  continue reading
 
The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based radiology and AI-based pathology are transforming patient lives through machine learning and data analytics, in some cases offering early disease warning systems and improving quality of…
  continue reading
 
Det har vært en historisk dag! President Zelenskyj har vært på digitalt besøk på Stortinget. Alle partiene - med ett unntak - deltok og er blitt enige om støttepakke til Ukraina. Vi er innom kommuneoppløsing, Nidaros Sosialdemokratisk Forum og PC har besøkt Norges Willy Wonka! En podkast av Henrik Asheim, Tina Bru og Peter Frølich Hosted on Acast. …
  continue reading
 
For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clin…
  continue reading
 
In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to cross-species organ transplantation and the latest in the evolving regulatory and reimbursement landscape, these stories captivated us and continue to herald …
  continue reading
 
Julefreden er i ferd med å senke seg. Henrik og PC oppsummerer 2022 med årets verste nyhetskavalkade. Tusen takk til alle som har lyttet, og sendt inn både spørsmål og innspill som har gjort det enda gøyere å lage podkast. Vi gleder oss til fortsettelsen i 2023! En podkast av Henrik Asheim, Tina Bru og Peter Frølich Hosted on Acast. See acast.com/p…
  continue reading
 
Loading …

Quick Reference Guide